{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:28:35Z","timestamp":1783628915782,"version":"3.55.0"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Favipiravir is an antiviral drug used to treat influenza and is also being investigated for the treatment of SARS-CoV-2. Its pharmacokinetic profile varies depending on ethnic group. The present research examines the pharmacokinetic features of favipiravir in healthy male Egyptian volunteers. Another goal of this research is to determine the optimum dissolution testing conditions for immediate release tablets. In vitro dissolution testing was investigated for favipiravir tablets in three different pH media. The pharmacokinetic features of favipiravir were examined in 27 healthy male Egyptian volunteers. The parameter \u201cAUC0-t\u201d vs. percent dissolved was used to develop level C in vitro in vivo correlation (IVIVC) to set the optimum dissolution medium to achieve accurate dissolution profile for favipiravir (IR) tablets. The in vitro release results revealed significant difference among the three different dissolution media. The Pk parameters of twenty-seven human subjects showed mean value of Cpmax of 5966.45\u2009ng\/mL at median tmax of 0.75\u2009h with AUC0-\u221e equals 13325.54\u2009ng.h\/mL, showing half-life of 1.25\u2009h. Level C IVIVC was developed successfully. It was concluded that Egyptian volunteers had comparable Pk values to American and Caucasian volunteers, however they were considerably different from Japanese subjects. AUC0-t vs. % dissolved was used to develop level C IVIVC to set the optimum dissolution medium. Phosphate buffer medium (pH 6.8) was found to be the optimum dissolution medium for in vitro dissolution testing for Favipiravir IR tablets.<\/jats:p>","DOI":"10.1055\/a-2061-7074","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T23:22:31Z","timestamp":1682378551000},"page":"349-354","source":"Crossref","is-referenced-by-count":4,"title":["Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation"],"prefix":"10.1055","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1883-169X","authenticated-orcid":false,"given":"Ehab R.","family":"Bendas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamdouh R.","family":"Rezk","sequence":"additional","affiliation":[{"name":"Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal A.","family":"Badr","sequence":"additional","affiliation":[{"name":"Pharmaceutics Department, Faculty of Pharmacy, Deraya University, New Minya, Egypt"},{"name":"Advanced Research Center, Nasr City, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"ref1","first-page":"608","article-title":"History of Virology","author":"MB A Oldstone","year":"2014","journal-title":"Encyclopedia of Microbiology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470015902.a0001091.pub2","volume-title":"Viral Capsids and Envelopes: Structure and Function. in ELS","author":"W Lucas","year":"2010"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.4476","article-title":"Viruses and disease: emerging concepts for prevention, diagnosis and treatment","volume":"235","author":"C S Herrington","year":"2015","journal-title":"J Pathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"B Hu","year":"2021","journal-title":"Nature Reviews Microbiology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"635337","DOI":"10.3389\/fmolb.2021.635337","article-title":"Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19","volume":"8","author":"R Bezbaruah","year":"2021","journal-title":"Front Mol Biosci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","article-title":"Antivirals for COVID-19: A critical review","volume":"9","author":"A Frediansyah","year":"2021","journal-title":"Clinical epidemiology and global health"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"P Richardson","year":"2020","journal-title":"The Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"R U Kadam","year":"2017","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","article-title":"Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines","volume":"47","author":"X Liu","year":"2020","journal-title":"Journal of Genetics and Genomics"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1021\/acscentsci.0c00747","article-title":"Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19","volume":"6","author":"R T Eastman","year":"2020","journal-title":"ACS central science"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"S Joshi","year":"2021","journal-title":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Z F Udwadia","year":"2021","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2147\/IJN.S315705","article-title":"Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics","volume":"16","author":"R Chen","year":"2021","journal-title":"International journal of nanomedicine"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1208\/s12248-019-0297-y","article-title":"First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing","volume":"21","author":"N Zaborenko","year":"2019","journal-title":"AAPS J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"106917","DOI":"10.1016\/j.microc.2021.106917","article-title":"A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling","volume":"172","author":"H M Marzouk","year":"2022","journal-title":"Microchem J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"114057","DOI":"10.1016\/j.jpba.2021.114057","article-title":"A novel LC-MS\/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers","volume":"199","author":"M I Morsy","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1002\/bmc.5098","article-title":"A novel, rapid and simple UPLC-MS\/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study","volume":"35","author":"M R Rezk","year":"2021","journal-title":"Biomed Chromatogr"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection","volume":"108","author":"Y X Du","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials","volume":"55","author":"V Madelain","year":"2016","journal-title":"Clinical pharmacokinetics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"103204","DOI":"10.1016\/j.ebiom.2020.103204","article-title":"Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19","volume":"63","author":"M G Ison","year":"2021","journal-title":"EBioMedicine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization Good Clinical Practice guideline","volume":"6","author":"J R Dixon","year":"1998","journal-title":"Qual Assur"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(13)60970-8","article-title":"Reconsidering the Declaration of Helsinki","volume":"381","author":"E J Emanuel","year":"2013","journal-title":"Lancet."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1183\/20734735.001918","article-title":"How to obtain informed consent for research","volume":"14","author":"S Manti","year":"2018","journal-title":"Breathe (Sheff)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ejps.2004.01.006","article-title":"Multiple level C in vitro\/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism","volume":"21","author":"N M Volpato","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/02537176211046525","article-title":"Z Scores, Standard Scores, and Composite Test Scores Explained","volume":"43","author":"C Andrade","year":"2021","journal-title":"Indian J Psychol Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.fjps.2018.03.001","article-title":"Mathematical prediction of pharmacokinetic parameters-an in-vitro approach for investigating pharmaceutical products for IVIVC","volume":"4","author":"V Rastogi","year":"2018","journal-title":"Future Journal of Pharmaceutical Sciences"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jiph.2022.01.013","article-title":"Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia","volume":"15","author":"A A Mutair","year":"2022","journal-title":"J Infect Public Health"},{"key":"ref30","first-page":"3516","volume":"88","author":"R G\u00fclhan","year":"2022","journal-title":"Pharmacokinetic characterization of favipiravir in patients with COVID-19"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cmi.2021.12.026","article-title":"Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial","volume":"28","author":"M Bosaeed","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-94-6351-086-8_2","volume-title":"One-sample T-test. Basic and advanced statistical tests","author":"A Ross","year":"2017"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/0974-2069.99622","article-title":"The use of Z-scores in paediatric cardiology","volume":"5","author":"H Chubb","year":"2012","journal-title":"Ann Pediatr Cardiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5414\/CP203936","article-title":"Bioequivalence study of two favipiravir tablet formulations in healthy male subjects","volume":"59","author":"O Sa\u011flam","year":"2021","journal-title":"International journal of clinical pharmacology and therapeutics"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1638\/2007-0139R.1","article-title":"Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus)","volume":"39","author":"U Bechert","year":"2008","journal-title":"J Zoo Wildl Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"20170213","DOI":"10.1098\/rsif.2017.0213","article-title":"The coefficient of determination R(2) and intra-class correlation coefficient from generalized linear mixed-effects models revisited and expanded","volume":"14 (134)","author":"S Nakagawa","year":"2017","journal-title":"J R Soc Interface"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/scipharm90010003","article-title":"The Development and the Validation of a Novel Dissolution Method of Favipiravir Film-Coated Tablets","volume":"90","author":"\u00d6 G\u00f6ktu\u011f","year":"2022","journal-title":"Scientia Pharmaceutica"},{"key":"ref38","volume-title":"editors. Understanding Biopharmaceutics Properties for Pharmaceutical Product Development and Manufacturing II \u2013 Dissolution and In Vitro- In Vivo Correlation","author":"D Zhou","year":"2010"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1002\/jps.24362","article-title":"Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls","volume":"104","author":"F Kesisoglou","year":"2015","journal-title":"J Pharm Sci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jps.1071","article-title":"In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers","volume":"90","author":"G Balan","year":"2001","journal-title":"J Pharm Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0939-6411(99)00016-8","article-title":"In vitro\/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers","volume":"48","author":"O A Lake","year":"1999","journal-title":"Eur J Pharm Biopharm"},{"key":"ref42","first-page":"449","article-title":"IVIVC approach based on carbamazepine bioequivalence studies combination","volume":"72","author":"I Gonz\u00e1lez-Garc\u00eda","year":"2017","journal-title":"Pharmazie"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2061-7074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:42:23Z","timestamp":1702291343000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2061-7074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":40,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2023,7,5]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2061-7074","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]}}}